Zentalis Pharmaceuticals (ZNTL) Revenue & Revenue Breakdown
Zentalis Pharmaceuticals Revenue Highlights
Zentalis Pharmaceuticals Revenue by Period
Zentalis Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2018-12-31 | $14.00K | - |
Zentalis Pharmaceuticals generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Zentalis Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $40.56M | 1827.76% |
| 2023-12-31 | $2.10M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Zentalis Pharmaceuticals generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Zentalis Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| VECT | VectivBio | $27.34M | $676.00K |
| ITOS | iTeos Therapeutics | $12.60M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GRCL | Gracell Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| INZY | Inozyme Pharma | - | - |
| OLMA | Olema Pharmaceuticals | - | - |
| ERAS | Erasca | - | - |
| ANNX | Annexon | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| SANA | Sana Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| ZNTL | Zentalis Pharmaceuticals | - | - |
ZNTL Revenue FAQ
What is Zentalis Pharmaceuticals’s yearly revenue?
Zentalis Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. ZNTL's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Zentalis Pharmaceuticals’s quarterly revenue?
Zentalis Pharmaceuticals's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $40.56M, a 1827.76% increase from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). ZNTL's quarterly revenue for Q4 2023 was $2.1M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Zentalis Pharmaceuticals’s revenue growth rate?
Zentalis Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.